Table 2 Changes of DXR-parameters between baseline and month 22 for the leflunomide and methotrexate group
Group | Baseline | Month 22 | Difference | Relative change | p-value | |
|---|---|---|---|---|---|---|
mean (SD) | mean (SD) | mean (SD) | ||||
Leflunomide | DXR-BMD in g/cm2 | 0.569 (0.088) | 0.561 (0.094) | −0.008 (0.024) | - 1.4 % | p < 0.05 |
DXR-MCI | 0.452 (0.095) | 0.442 (0.098) | −0.010 (0.022) | - 2.2 % | p < 0.05 | |
DXR-CT in cm | 0.185 (0.038) | 0.181 (0.040) | −0.004 (0.009) | - 2.2 % | p < 0.05 | |
DXR-Win cm | 0.822 (0.073) | 0.823 (0.073) | 0.001 (0.006) | +0.1 % | p = n. s. | |
Methotrexate | DXR-BMD in g/cm2 | 0.578 (0.070) | 0.553 (0.080) | −0.024 (0.037) | - 4.3 % | p < 0.05 |
DXR-MCI | 0.447 (0.076) | 0.425 (0.078) | −0.022 (0.027) | - 4.9 % | p < 0.05 | |
DXR-CT in cm | 0.186 (0.029) | 0.176 (0.032) | −0.010 (0.014) | - 5.4 % | p < 0.05 | |
DXR-in cm | 0.840 (0.086 | 0.835 (0.093) | −0.005 (0.031) | - 0.6 % | p = n. s. |